PL3313865T3 - Syntetyczne związki peptydowe i sposoby zastosowania - Google Patents

Syntetyczne związki peptydowe i sposoby zastosowania

Info

Publication number
PL3313865T3
PL3313865T3 PL16815455T PL16815455T PL3313865T3 PL 3313865 T3 PL3313865 T3 PL 3313865T3 PL 16815455 T PL16815455 T PL 16815455T PL 16815455 T PL16815455 T PL 16815455T PL 3313865 T3 PL3313865 T3 PL 3313865T3
Authority
PL
Poland
Prior art keywords
methods
synthetic peptide
peptide compounds
compounds
synthetic
Prior art date
Application number
PL16815455T
Other languages
English (en)
Inventor
Neel K. Krishna
Kenji Cunnion
Original Assignee
Realta Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Holdings, Llc filed Critical Realta Holdings, Llc
Publication of PL3313865T3 publication Critical patent/PL3313865T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/12011Astroviridae
    • C12N2770/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16815455T 2015-06-26 2016-06-24 Syntetyczne związki peptydowe i sposoby zastosowania PL3313865T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185202P 2015-06-26 2015-06-26
EP16815455.7A EP3313865B1 (en) 2015-06-26 2016-06-24 Synthetic peptide compounds and methods of use
PCT/US2016/039421 WO2016210370A2 (en) 2015-06-26 2016-06-24 Synthetic peptide compounds and methods of use

Publications (1)

Publication Number Publication Date
PL3313865T3 true PL3313865T3 (pl) 2021-10-25

Family

ID=57586008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16815455T PL3313865T3 (pl) 2015-06-26 2016-06-24 Syntetyczne związki peptydowe i sposoby zastosowania

Country Status (6)

Country Link
US (1) US10933116B2 (pl)
EP (1) EP3313865B1 (pl)
JP (2) JP6820917B2 (pl)
ES (1) ES2875498T3 (pl)
PL (1) PL3313865T3 (pl)
WO (1) WO2016210370A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
EP3740074B1 (en) * 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
AU2020221342A1 (en) * 2019-02-15 2021-07-15 Realta Holdings, Llc PIC1 variants with improved solubility and methods of using the same
IL301441A (en) * 2020-09-30 2023-05-01 Realta Life Sciences Inc Peptides and methods of use
WO2022094367A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
CA3194447A1 (en) * 2020-11-09 2022-05-12 Neel K. Krishna Peptide formulations and methods of use
CN116472037A (zh) * 2021-03-12 2023-07-21 国立大学法人新潟大学 由溶血反应诱发的肾损伤的抑制
EP4230200B1 (en) * 2021-03-12 2025-06-11 Niigata University Agent for inhibiting renal damage induced by rhabdomyolysis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
WO2005023296A1 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of rheumatic diseases
US20070012617A1 (en) 2003-09-05 2007-01-18 Sadakatsu Suzuki Method for producing micro-porous film of thermoplastic resin
WO2005023195A2 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007145806A2 (en) 2006-06-15 2007-12-21 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
US7956161B2 (en) 2007-04-11 2011-06-07 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
ES2688589T3 (es) 2010-07-21 2018-11-05 Eastern Virginia Medical School Compuestos peptídicos para regular el sistema del complemento
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors

Also Published As

Publication number Publication date
JP2018524402A (ja) 2018-08-30
EP3313865A2 (en) 2018-05-02
US10933116B2 (en) 2021-03-02
WO2016210370A3 (en) 2017-02-23
WO2016210370A2 (en) 2016-12-29
EP3313865B1 (en) 2021-04-07
CA2987141A1 (en) 2016-12-29
JP6992201B2 (ja) 2022-02-03
ES2875498T3 (es) 2021-11-10
US20200254053A1 (en) 2020-08-13
JP6820917B2 (ja) 2021-01-27
JP2021063106A (ja) 2021-04-22
EP3313865A4 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL257636A (en) Anti-tigit antibodies and methods of use
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
SG11201803213XA (en) Glycan-interacting compounds and methods of use
SG11201706583PA (en) Anti-pvrig antibodies and methods of use
IL313511A (en) Compounds acting on glycans and methods of using them
PL3089971T3 (pl) Związki i sposoby ich zastosowania
IL282482A (en) Variants of protoxin-II and methods of use
PL3313865T3 (pl) Syntetyczne związki peptydowe i sposoby zastosowania
GB201514760D0 (en) Compounds and method of use
HUE057883T2 (hu) Peptid készítmények és felhasználási módszerek
IL282508A (en) Variants of protoxin-II and methods of use
ZA201606450B (en) Compounds and their methods of use
IL247448A0 (en) Peptides and methods of use
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
GB201403697D0 (en) Compounds and methods of use
GB201504211D0 (en) Use of peptides